Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
03:17am, Friday, 06'th Mar 2026
LOS ANGELES, March 6, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. ("Vista
New York, New York--(Newsfile Corp. - March 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between
NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN). Such
Bronstein, Gewirtz & Grossman LLC Urges Vistagen Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
12:00pm, Thursday, 05'th Mar 2026
New class action for Vistagen (VTGN) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 3/16/2026.
VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
09:40am, Thursday, 05'th Mar 2026
LOS ANGELES, March 05, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Vistagen Therapeutics, Inc. (�
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ:
VTGN Deadline: VTGN Investors Have Opportunity to Lead Vistagen Therapeutics, Inc. Securities Fraud Lawsuit
03:01am, Thursday, 05'th Mar 2026
NEW YORK, March 5, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 202
Brokerages Set VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Price Target at $0.95
01:10am, Thursday, 05'th Mar 2026
Shares of VistaGen Therapeutics, Inc. (NASDAQ: VTGN - Get Free Report) have earned a consensus rating of "Reduce" from the five brokerages that are covering the company, Marketbeat reports. One resear
NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1,
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
UPCOMING DEADLINE: Vistagen Therapeutics, Inc. (VTGN) Securities Fraud Class Action - March 16, 2026 Lead Plaintiff Deadline
10:40am, Wednesday, 04'th Mar 2026
Vistagen Investors With Significant Losses Are Encouraged To Contact Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson To Discuss Their Legal Rights If you purchased or acquired s
LEVI & KORSINSKY, LLP: TIMELINE OF ALLEGED MISREPRESENTATIONS IN VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION
09:00am, Wednesday, 04'th Mar 2026
DEADLINE: March 16, 2026 NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) to contact the firm before
NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Vistagen Therapeutics, Inc. ("Vistagen" or the "Company") (NASDAQ: VTGN) of a class action securities lawsuit. CLAS
New York, New York--(Newsfile Corp. - March 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Vistagen Therapeutics, Inc. (“Vistagen” or the “Company”) (NASDAQ: VTGN)
